• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

解析 CAR T 细胞激活与耗竭的信号平衡

Unraveling the Signaling Balance of Activation and Exhaustion of CAR T Cells.

机构信息

Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Charlestown, MA 02129, USA; Harvard Medical School, Boston, MA 02115, USA.

Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Charlestown, MA 02129, USA; Harvard Medical School, Boston, MA 02115, USA.

出版信息

Cancer Cell. 2020 Feb 10;37(2):143-144. doi: 10.1016/j.ccell.2020.01.006.

DOI:10.1016/j.ccell.2020.01.006
PMID:32049043
Abstract

CAR T cells with different costimulation domains have proven clinical efficacy in leukemia and lymphoma but have different kinetics of activation, antigen sensitivity, and susceptibility to exhaustion. Two recent studies identified that these functions are shaped by a balance among opposing signaling complexes and transcription factors competing for binding motifs.

摘要

嵌合抗原受体 T 细胞(CAR T 细胞)带有不同的共刺激结构域,已被证明在白血病和淋巴瘤中有临床疗效,但它们的激活动力学、抗原敏感性和对衰竭的易感性不同。最近的两项研究表明,这些功能是由相互竞争结合基序的拮抗信号复合物和转录因子之间的平衡所塑造的。

相似文献

1
Unraveling the Signaling Balance of Activation and Exhaustion of CAR T Cells.解析 CAR T 细胞激活与耗竭的信号平衡
Cancer Cell. 2020 Feb 10;37(2):143-144. doi: 10.1016/j.ccell.2020.01.006.
2
Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function.嵌合抗原受体信号的磷酸化蛋白质组学分析揭示了影响细胞功能的动力学和定量差异。
Sci Signal. 2018 Aug 21;11(544):eaat6753. doi: 10.1126/scisignal.aat6753.
3
Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype.优化嵌合抗原受体 T 细胞的制造条件,以利于具有中央记忆表型的细胞。
Cytotherapy. 2019 Jun;21(6):593-602. doi: 10.1016/j.jcyt.2019.03.003. Epub 2019 Apr 8.
4
A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.一种新型嵌合抗原受体,包含 JAK-STAT 信号域,介导优越的抗肿瘤效应。
Nat Med. 2018 Mar;24(3):352-359. doi: 10.1038/nm.4478. Epub 2018 Feb 5.
5
Research Techniques Made Simple: CAR T-Cell Therapy.研究技巧解析:嵌合抗原受体 T 细胞疗法。
J Invest Dermatol. 2018 Dec;138(12):2501-2504.e1. doi: 10.1016/j.jid.2018.09.002. Epub 2018 Sep 19.
6
CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.嵌合抗原受体 T 细胞增强对 B 细胞成熟抗原的敏感性,用于靶向治疗 B 细胞非霍奇金淋巴瘤和多发性骨髓瘤。
Mol Ther. 2018 Aug 1;26(8):1906-1920. doi: 10.1016/j.ymthe.2018.06.012. Epub 2018 Jun 18.
7
CAR-T Engineering: Optimizing Signal Transduction and Effector Mechanisms.嵌合抗原受体 T 细胞工程:优化信号转导和效应机制。
BioDrugs. 2019 Dec;33(6):647-659. doi: 10.1007/s40259-019-00384-z.
8
Updates in Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Lymphoma and Leukemia from the Annual Meeting of American Society of Hematology 2019.2019 年美国血液学会年会:嵌合抗原受体 T 细胞(CAR-T)疗法治疗淋巴瘤和白血病的最新进展。
Crit Rev Oncol Hematol. 2020 Aug;152:103007. doi: 10.1016/j.critrevonc.2020.103007. Epub 2020 May 29.
9
Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products.嵌合抗原受体 T 细胞疗法治疗侵袭性 B 细胞非霍奇金淋巴瘤:疗效、毒性和比较嵌合抗原受体产品。
Expert Opin Biol Ther. 2019 Nov;19(11):1157-1164. doi: 10.1080/14712598.2019.1644316. Epub 2019 Jul 25.
10
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells.一种针对实体瘤和血液癌细胞的嵌合抗原受体T细胞的实时效价测定法。
J Vis Exp. 2019 Nov 12(153). doi: 10.3791/59033.

引用本文的文献

1
Mapping Current Research Status and Emerging Frontiers of T-Cell Exhaustion: A Comprehensive Data-Mining-Based Study.绘制T细胞耗竭的当前研究现状与新兴前沿:一项基于全面数据挖掘的研究
Ann Surg Oncol. 2025 Aug 18. doi: 10.1245/s10434-025-18066-2.
2
Advances in the relationship between AP-1 and tumorigenesis, development and therapy resistance.AP-1与肿瘤发生、发展及治疗耐药性之间关系的研究进展
Discov Oncol. 2025 Jan 20;16(1):61. doi: 10.1007/s12672-025-01783-1.
3
IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases.
表达 IL-10 的 CAR T 细胞可抵抗功能障碍,介导实体瘤和转移灶的持久清除。
Nat Biotechnol. 2024 Nov;42(11):1693-1704. doi: 10.1038/s41587-023-02060-8. Epub 2024 Jan 2.
4
Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies.嵌合抗原受体 T 细胞耗竭在血液系统恶性肿瘤治疗期间。
Biomed Res Int. 2020 Oct 23;2020:8765028. doi: 10.1155/2020/8765028. eCollection 2020.
5
Targeted Cellular Micropharmacies: Cells Engineered for Localized Drug Delivery.靶向细胞微型药库:用于局部给药的工程细胞
Cancers (Basel). 2020 Aug 5;12(8):2175. doi: 10.3390/cancers12082175.